Panacea Life Sciences Holdings Past Earnings Performance
Past criteria checks 0/6
Panacea Life Sciences Holdings's earnings have been declining at an average annual rate of -30.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 23.2% per year.
Key information
-30.8%
Earnings growth rate
-34.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -23.2% |
| Return on equity | n/a |
| Net Margin | -277.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Panacea Life Sciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3 | -8 | 1 | 0 |
| 31 Dec 23 | 2 | -8 | 1 | 0 |
| 30 Sep 23 | 2 | -8 | 1 | 0 |
| 30 Jun 23 | 2 | -8 | 1 | 0 |
| 31 Mar 23 | 2 | -8 | 1 | 0 |
| 31 Dec 22 | 2 | -9 | 1 | 0 |
| 30 Sep 22 | 2 | -10 | 2 | 0 |
| 30 Jun 22 | 2 | -10 | 2 | 0 |
| 31 Mar 22 | 2 | -8 | 1 | 0 |
| 31 Dec 21 | 2 | -5 | 2 | 0 |
| 30 Sep 21 | 2 | -3 | 1 | 0 |
| 30 Jun 21 | 3 | -3 | 1 | 0 |
| 31 Mar 21 | 6 | -4 | 3 | 0 |
| 31 Dec 20 | 9 | -5 | 3 | 0 |
| 30 Sep 20 | 10 | -3 | -2 | 0 |
| 30 Jun 20 | 9 | -1 | -1 | 0 |
| 31 Mar 20 | 6 | -2 | 0 | 0 |
| 31 Dec 19 | 2 | -3 | 1 | 0 |
Quality Earnings: PLSH is currently unprofitable.
Growing Profit Margin: PLSH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PLSH is unprofitable, and losses have increased over the past 5 years at a rate of 30.8% per year.
Accelerating Growth: Unable to compare PLSH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PLSH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: PLSH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.